Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
abbreviated, ADME, ANDA, benchmark, bioequivalence, BLA, Book, bound, BPCA, carryforward, certify, certifying, cited, column, conflict, contrast, decree, disincentivizing, downstream, embedded, exemplified, extravasation, FDC, fulfill, FXII, FXIIKO, GLP, Hatch, HHS, ID, ingredient, inline, insert, KOMPLETE, KONFIDENT, language, launched, likewise, living, meant, metric, molecularly, myriad, NaN, NCE, NDABLA, omission, Orange, organizational, panel, Paragraph, paw, PHS, PKa, pretreatment, QD, rat, referenced, restoration, resubmission, Russia, satisfactory, sebestralstat, sebetralstat, sebetralstrat, sebetratstat, send, timeframe, tracheal, Ukraine, undergone, unfounded, upcoming, version, viii, Waxman, whistleblower, widespread
Removed:
absorbed, accumulation, acetonide, adding, Aerpio, Affordability, aflibercept, agree, Alimera, Allegro, Allergan, ascending, Avastin, baseline, bevacizumab, binding, bloodstream, Boehringer, branded, breakdown, calendar, capsule, captioned, Carbylan, cataract, central, characterization, collected, comparative, comparison, complication, concurrently, content, corrected, correlated, corticoid, corticosteroid, derived, detailed, dexamethasone, diligent, displayed, Dohme, dominated, dramatic, enabled, equal, essentially, establishment, exact, explore, Eylea, favorably, fed, fluocinolone, fraction, gap, gavage, GlaxoSmithKline, GMP, halt, Harvard, highest, home, implanted, importance, improving, infused, Ingelheim, inhaled, innovator, instilled, Institute, intraocular, invasive, investigate, Joslin, justified, laser, leaving, led, lesser, lluvien, macula, male, mandate, mandatory, methodology, mild, minimal, minimum, modality, negotiated, notified, October, Ohr, oncology, onsite, ophthalmic, ophthalmology, optimize, optimum, osmotic, outpatient, oversee, owed, Oxurion, Ozurdex, passed, peer, pharmacodynamic, pioneered, platform, poverty, preceding, President, protective, quantified, ranibizumab, recommend, reducing, Regeneron, regime, release, repealing, replace, reproductive, rest, retinopathy, Roche, roughly, SAE, School, screened, selection, served, sham, shared, showed, solution, stolen, subcutaneously, subfield, suffered, systemic, tablet, theft, threshold, tolerability, tolerated, toxicity, unfold, upfront, validate
Filing tables
Filing exhibits
KALV similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, T. Andrew Crockett, Chief Executive Officer of KalVista Pharmaceuticals, Inc. (the “Company”), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
•
this Annual Report on Form 10-K of the Company for the year ended April 30, 2022 (the “Report”), as filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
•
the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company for the periods presented therein.
Date: July 7, 2022 | By: | /s/ T. Andrew Crockett |
|
| T. Andrew Crockett Chief Executive Officer (Principal Executive Officer)
|